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Abstract
Background: Schizophrenia is associated with a two to three fold excess mortality. Both natural and unnatural
causes were reported. However, there is dearth of evidence from low and middle income (LAMIC) countries,
particularly in Africa. To our knowledge this is the first community based report from Africa.
Methods: We followed a cohort of 307 (82.1% males) patients with schizophrenia for five years in Butajira, rural
Ethiopia. Mortality was recorded using broad rating schedule as well as verbal autopsy. Standardized Mortality Ratio
(SMR) was calculated using the mortality in the demographic and surveillance site as a reference.
Result: Thirty eight (12.4%) patients, 34 men (11.1%) and 4 women (1.3%), died during the five-year follow up
period. The mean age (SD) of the deceased for both sexes was 35 (7.35). The difference was not statistically
significant (p = 0.69). It was 35.3 (7.4) for men and 32.3 (6.8) for women. The most common cause of death was
infection, 18/38 (47.4%) followed by severe malnutrition, 5/38 (13.2%) and suicide 4/38 (10.5%). The overall SMR
was 5.98 (95% CI = 4.09 to7.87). Rural residents had lower mortality with adjusted hazard ratio (HR) of 0.30 (95% CI
= 0.12-0.69) but insidious onset and antipsychotic treatment for less than 50% of the follow up period were
associated with higher mortality, adjusted HR 2.37 (95% CI = 1.04-5. 41) and 2.66(1.054-6.72) respectively.
Conclusion: The alarmingly high mortality observed in this patient population is of major concern. Most patients
died from potentially treatable conditions. Improving medical and psychiatric care as well as provision of basic
needs is recommended.
Background
Schizophrenia is often called a ‘life shortening disease’
[1]. Mortality is increasingly recognized as a crucial out-
come measure for quality of care patients with schizo-
phrenia receive [2,3]. Several studies reported that
people with schizophrenia live shorter lives compared
with the general population [4]. Most of the reports
come from inpatients registers, death registers or cohort
of patients. These have found a two to three fold
increase in all cause mortality compared with the gen-
eral population, moreover; when compared with other
mental disorders, having the diagnosis of schizophrenia
carried a higher risk of mortality [5-9]. Factors contri-
buting to premature death in people with schizophrenia
include suicide, untreated somatic conditions, and
adverse effects of psychotropic medications to mention
a few [10]. A recent study which compared survival sta-
tus of people with diabetes in the UK showed that hav-
ing a diagnosis of schizophrenia increased the risk of
death from diabetes by almost two fold [11].
Most of the reports come from centers in industria-
lized countries. Although there is paucity of data from
low and middle income (LAMIC) countries, the existing
data shows that there is high level of mortality in
patients with schizophrenia from these countries with
pooled Standardized Mortality Ratios (SMR) comparable
with those patients who live in industrialized countries
[12]. The notion that schizophrenia has a benign course
and outcome in LAMIC countries has been challenged
by several reports which showed poor outcome for
patients from these countries. These reports emerge lar-
gely from countries in Africa, Asia and Latin America
which are called LAMIC countries [13,14]. Reports of
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mortality into account.
The aim of this study was to determine the five- year
mortality in a rural community based cohort with schi-
zophrenia and to describe the causes of death as well as
to suggest some interventions for potentially modifiable
risk factors. We hypothesized that the cohort in our
study would have high level of mortality. In addition to
the general report of excess mortality, our hypothesis
was based on reports that associate poor clinical out-
come with increased risk of mortality [15]. Our cohort
was previously reported to have poor short-term clinical
outcome with a large proportion of patients having had
chronic or relapsing course [16].
Methods
Study site and Establishment of the cohort
Details of the study settings and methods screening and
diagnostic methods and establishment of the cohort can
be found in a previously published paper [16]. The
study was done in Butajira district, which houses a
demographic surveillance site (DSS), located 132 km
south of the capital city, Addis Ababa. The presence of
the DSS offered a unique opportunity to calculate age
and sex standardized mortality ratios.
The cohort was identified through a two-stage sampling
design: an initial screen to identify potential cases with
severe mental disorders (schizophrenia, bipolar disorder
and depressive disorder) and a second confirmatory assess-
ment stage. The initial screen targeted the entire adult
population of the 44 sub-districts, ages 15-49, estimated to
be 83,282 [17]. This initial screen involved a supervised,
door-to-door survey of the target population using the
affective and psychoses modules of the Composite Interna-
tional Diagnostic Interview (CIDI), version 2.1 [18]. The
CIDI was administered to 68,378 individuals (82% of the
target population). Key informants were also employed to
augment the screening with the CIDI interview. In the sec-
ond stage, confirmatory diagnostic assessment was con-
ducted for all CIDI positives using SCAN version 2.1 [19].
The following three criteria were selected for inclu-
sion: age between 15 and 49 years; residence of at least
6 months in the study area prior to inclusion and meet-
ing criteria for the diagnosis of schizophrenia according
to ICD-10 [20] after a SCAN interview.
A total of 2,878 individuals were identified as positive
for the psychosis and mood section through the initial
screen and 2,285 (79.4%) volunteered for the SCAN
interview. Of those interviewed with SCAN, 321 were
diagnosed as having schizophrenia.
Follow-up and confirmation of mortality
Field workers employed by the research project were
assigned to each patient to facilitate the follow up.
Patient’s monthly clinical status was recorded by either
a psychiatry resident or an experienced psychiatry nurse.
Annual SCAN was done by the psychiatry resident. The
cohort was followed-up for the duration of 5 years.
Deaths were identified by the field workers and the
causes for death were established by physicians through
direct interviews of close relatives and local health work-
ers when appropriate. The clinical and functional status
of the deceased patients around the time of death was
recorded by a psychiatry resident. Both broad rating
schedule and verbal autopsy questionnaires were used to
gather information as required by the situation [21,22].
The broad rating schedule was developed by the WHO
for recording broad range of information including
severity of symptoms and functioning from multiple
sources including informants and records and can be
used for cases lost to follow-up as well as deceased
cases [22].
Data management and analysis
Full time data entry clerk first checked all interview
forms in the field for completeness, accuracy and consis-
tency. Epi-info program (version 6.2) was used for data
entry. Double data-entry and consistency checks were
employed to assure the quality of data entry.
Stata version 11 (Stata Corp) was used for both
descriptive analysis and survival analysis. The age and
sex standardized mortality ratio was calculated using
mortality in the DSS as a reference [23]. Cox regression
was used to evaluate the effect of socio-demographic
and clinical characteristics on time to death.
Ethical Considerations
E t h i c a la p p r o v a lo ft h es t u d yw a so b t a i n e df r o mt h e
Faculty of Medicine, Addis Ababa University. All partici-
pants provided consent to be interviewed. For the cases
identified by the research a psychiatric clinic was estab-
lished which provided free medication during the fol-
low-up period.
Result
Demographic characteristics of the deceased
The initial cohort comprised a total of 321 cases with
schizophrenia. We had complete data for 307 of the 321
patients (95.6%) that were included in the initial cohort,
252 (82.1%) males and 55 (17.9%) females at the time of
analysis of the 5-year follow up. The majority were mar-
ried (51.8%), had no formal education (53.7%), Muslim
by religion (74.6%) and were from a rural setting
(76.8%) (Table 1).
All cause mortality
A total of 38 (12.4%) patients, thirty four men (11.1%)
and four women (1.3%), died during the 5-year follow-
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sexes was 35 (7.4). It was 35.3 (7.4) for men and 32.3
(6.8) for women. The difference was not statistically sig-
nificant (p = 0.69).
Cause and place of death
The most common cause of death was infection such
as malaria, tuberculosis and severe diarrheal disease
18/38 (47.4%) followed by severe malnutrition 5/38
(13.2%) and suicide 4/38 (10.5%). The suicide cases
were exclusively men. One of them committed suicide
by setting fire on himself and burnt to death. One
male and one female patient were hit by running cars
and died. One of them died immediately on the road
while the other was taken to a clinic but couldn’tb e
saved. The causes of death for three (7.9%) were unde-
termined. One of these was a homeless person who
was known to have been drinking and smoking exces-
sively. He was found dead in an abandoned house and
was presumed to have died from natural causes, pre-
sumably from the complication of his habit of heavy
alcohol drinking. The other two reportedly died sud-
denly, and we were unable to establish causes of death
for these.
Place of death for the majority (78.9%) was at home.
For more than half of the deceased their death was
either caused or related with their mental illness. Only
2 of the cases were in remission during the time of
death and only 3 had a GAF score of 60 or more
(Table 2).
Mortality rate and standardized mortality ratio (SMR)
The mortality rate for study population was 8,661/
100,000 for men (mortality rate for the reference popu-
lation = 2,202.8/100,000) and 5,006/100,000 for women
(reference population = 1,802/100,000). The overall age
and sex standardized mortality ratio (SMR) was 5.98
(95% CI = 4.09-7.87). The total SMR was 6.27(95% CI =
4.16-8.38) for men and 4.3 (95% CI = 1.02-8.52) for
women (Table 3).
Correlates of Mortality
In a Cox regression analysis of time to death where
socio-demographic and clinical correlates were include
as predictor variables urban/semi-urban residence (Fig-
ure-1) and insidious onset of illness were significantly
associated with increased risk of mortality with
adjusted hazard ratio (HR) for rural residence of 0.30
(95% CI = 0.12-0.69) and adjusted HR for insidious
onset of 2.37 (95% CI = 1.04-5. 41). Treatment with
antipsychotics for less than 50% of the follow-up time
(Figure-2) was also significantly associated with higher
mortality with adjusted HR of 2.66(95%CI: 1.054-6.72)
(Table 4). The increased mortality among urban dwell-
ers and those patients who were not taking antipsycho-
tic medications for at least 50% of the follow-up period
Table 1 Sociodemographic characteristics of the cases with schizophrenia in Butajira, Ethiopia
Characteristics Male Female Total
(deceased)
n = 252 (34)
% (deceased)
82.1 (13.5)
(deceased)
n = 55 (4)
%(deceased)
17.9(7.3)
(deceased)
n = 307(38)
% (deceased)
100(12.4)
Age (307)*
15-24 39 (4) 15.5 (1.6) 18 (1) 32.7(1.8) 57(5) 18.6 (1.6)
25-34 106 (14) 42.1 (5.6) 17(2) 30.9(3.6) 123(16) 40.1(5.2)
35-49 73(16) 29 (6.3) 16(1) 29(1.8) 89(17) 29 (5.5)
Marital Status (307)
Single 67(8) 26.6 (3.2) 11(2) 20 (3.6) 78 (10) 25.4(3.3)
Married 116(21) 46.0 (8.3) 21(1) 38.2(1.8) 137(22) 44.6(7.2)
Other 35(5) 13.9(2) 19(1) 34.5(1.8) 54(6) 17.6(2)
Education(307)
No formal education 103(21) 40.9(8.3) 38(3) 69.1(5.5) 141(24) 45.9(7.8)
Elementary 73(8) 29(3.2) 8(1) 14.5(1.8) 81(9) 26.4(2.9)
Education 42(5) 16.7(2) 5(0) 9.1(0) 47(5) 15.3(1.6)
Secondary and above
Religion (307)
Muslim 172(25) 68.3(9.9) 30(2) 54.5(3.6) 202(27) 65.8(8.8)
Christian 46(9) 18.3(3.6) 21(2) 38.2(3.6) 67(11) 21.8(3.6)
Residence (307)
Urban/Semiurban 41(12) 16.3(4.8) 16(2) 29.1(3.6) 57(14) 18.6(4.6)
Rural 177(22) 70.2(8.7) 35(2) 63.6(3.6) 212(24) 69(7.8)
*data was available for 307 cases though cases identified in the original cohort were 321.
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Figures 1 and 2.
Discussion
Our report on mortality in schizophrenia is one of the
few population based studies coming from LAMIC
countries. Even most reports from high-income coun-
tries on schizophrenia mortality come from hospital
based studies. Participants of our cohort were predomi-
nantly treatment naïve at the time of enrolment identi-
fied through a house-to-house population survey. A very
rigorous follow-up of patients on monthly basis enabled
us to determine the mental status of our study partici-
pants and their functioning around the time of death. It
was also possible to describe the possible causes of
death using verbal autopsy [21]. The presence of a DSS
site enabled us to calculate the SMR [23].
Mortality
It is a well established fact that people with schizophre-
nia live shorter than their healthy counterparts, having a
2-3 fold increase in mortality [1,4,12]. In our study
which reported a five-year mortality, we found a six fold
increase in overall mortality (overall SMR = 5.98); men
h a dt h eh i g h e s tm o r t a l i t y( S M R=6 . 2 7 )c o m p a r e dw i t h
females (SMR = 4.3), and it was much higher than what
has been reported from different countries so far. The
absolute number of death was also one of the highest in
the world, 12% of the patients died in 5 years. The
mean age of death was also very low: men died approxi-
mately 14 years and women 20 years younger than the
reference population. Life expectancy at birth was 49.3
and 52. 3 years for men and women respectively [23].
It is worth mentioning here that direct comparison
with other reports may not be appropriate given the dif-
ference in sampling methods and the study setting such
as use of hospitalized patients. Caution is needed when
comparing SMRs that come from different populations
Table 2 Status of the schizophrenia cohort after 5 years
of follow-up in Butajira, Ethiopia
Characteristics Men
(N = 252)
Women
(N = 55)
Total
(N = 307)
No. % No. % No. %
Alive: completed 5-year follow up 180 71.4 42 13.7 222 72.3
Refusal 9 3.6 0 0 9 2.9
Out migrated 9 3.6 2 0.65 11 3.6
Vagrant 6 2.4 1 0.32 7 2.3
Untraceable 1 0.4 0 0 1 0.3
Deceased: 34 13.5 4 7.3 38 12.4
Infection: malaria, TB... 15 44.1 3 75 18 47.4
Severe malnutrition 5 14.7 0 0 5 13.2
Suicide 4 11.8 0 0 4 10.5
Hit by Car 1 2.9 1 25 2 5.3
Other natural causes 6 15.8 0 6 15.9
Unknown 3 7.9 3 7.9
Relation with mental illness
Caused 9 26.5 0 0 9 23.7
Related 11 32.4 1 25 12 31.6
Independent 9 26.5 2 50 11 28.9
Undetermined 5 14.7 1 25 6 15.8
Place of death
Home 27 79.4 3 30 78.9
Health facility 2 5.9 1 3 7.9
Other places 5 14.7 0 5 13.2
GAF score around death
< 60 27 79.4 2 50 29 76.3
≥ 60 2 5.9 1 25 3 7.9
unknown 5 14.7 1 25 6 15.8
MSE around death
Remission 2 5.9 0 0 2 5.3
Partial remission 7 20.6 1 25 8 21.0
In episode 23 67.6 3 75 26 68.4
Undetermined 2 5.9 0 0 2 5.3
Table 3 Age and Sex Standardized Mortality Ratio (SMR) of patients with schizophrenia in Butajira, Ethiopia*
Age
Group
Men Women
Observed
Deaths
Expected
death
Observed/Expected
Mortality
(SMR)
95% CI Observed
Deaths
Expected
death
Observed/Expected
Mortality
(SMR)
95% CI
15-24 4 0.73 5.48 0.11-
10.85
1 0.19 5.26 5.05-
15.57
25-34 14 2.23 6.28 2.99-
9.57
2 0.29 6.9 -2.66-
16.5
35-49 16 2.95 5.42 2.76-
8.18
1 0.53 1.89 -1.81-
5.59
Total 34 5.42 6.27 4.16-
8.38
4 0.93 4.3 1.02-
8.52
*Overall SMR = 5.98 (95% CI = 4.09-7.87)
Teferra et al. BMC Psychiatry 2011, 11:165
http://www.biomedcentral.com/1471-244X/11/165
Page 4 of 9as it might be affected by the mortality rate in the refer-
ence population [24]. But, there are some community
based reports which we can make a reasonable compari-
son with. A community based 10 year mortality from
China reported an overall SMR of 4.0 (95% CI = 2.4-
5.8). Similar to our cohort males had higher SMR than
females [25]. One main difference in the current study
and the China study is the duration of follow-up. In the
current study we are reporting the 5- year follow up
and the length of the follow-up time may contribute to
higher mortality as most patients die during early stages
of follow up [26,27]. Another study from a LAMIC
country (Bali) which reported a similar SMR to ours
(5.98) was based on hospitalized patients; similar to our
finding, men had higher SMR (7.11) than women (4.05)
[28]. However, other reports from LAMIC countries
reported low rates of mortality. For instance, a study
from Taiwan, which came from a linkage data of a large
s a m p l eo fi n p a t i e n t s ,r e p o r t e dS M Ro f2 . 7 0[ 2 9 ] .I nt h e
WHO multi-center study that reported a 15- and 25-
year follow-up of cases from Chandigarh (Rural and
urban), Agra and Cali, the SMR was around 2-3, but a
high proportion of drop-out rate, as high as 40 percent
in some sites, could be one reason for the low mortality
in these studies [24].
Probable causes of death
Not surprisingly, infectious causes were the most com-
mon causes of death in our schizophrenia cohort unlike
reports from high-income countries for which non-com-
municable diseases such as cardiovascular diseases, neo-
plasms, metabolic disturbances and possibly
psychotropic medications and smoking related mortality
[6,8,27,30]. Butajira has diverse climate and topography
ranging from low land to high land. There are no special
disease conditions peculiar to the district. As it is typical
for the country, infectious diseases are common in the
district including malaria [31], TB and HIV [32] contri-
buting to 53% of the overall mortality that occurred in
the Butajira DSS site [33]. Interestingly, despite the HIV
pandemic, there is a trend of decline in mortality
observed in young people in the Butajira DSS in the
Figure 1 Kaplan-Meier Curve showing survival probability and place of residence in people with schizophrenia: a five-year follow-up
in Butajira, Ethiopia.
Teferra et al. BMC Psychiatry 2011, 11:165
http://www.biomedcentral.com/1471-244X/11/165
Page 5 of 9past 18 years [34]. We had no data regarding the HIV
status of our cohort.
The district is prone to periodic draught leading to
food shortage, but the severe malnutrition observed in
the patient groups is more than what one would see in
the general adult population suggesting possible neglect
(or preferential treatment of healthy groups of the
family in times of shortage).
Well designed studies describing causes of mortality in
schizophrenia are lacking in Africa. Two hospital based
10 year mortality reports from Nigeria found that the
commonest cause of death was infectious as was found
in our study [35,36]. It is not possible to estimate gen-
eral mortality related to schizophrenia based on the two
Nigerian studies because they didn’tr e p o r ts p e c i f i c
diagnosis.
Unfortunately, we couldn’t calculate the cause specific
SMR because of lack of reference data in the area. This
limits comparison of our finding with other studies.
However, the crude figure among patients with
schizophrenia dying from unnatural causes, i.e. suicide
and accident (15.8%), was much higher than the propor-
tion who died from injuries over a five year period of
observation in a subsample of the general population
within the Butajira district (1.7%) [21]. It is well known
that people with schizophrenia have high rates of suicide
compared with the general population [37,38]. The pro-
portion of patients who committed suicide was higher
than reports from other LAMIC countries [39]. Interest-
ingly, all the suicide cases were men unlike reports from
mainland China where more females with schizophrenia
commit suicide [40].
Mortality as an outcome measure
Mortality has been mentioned as an important measure
of outcome in the course of schizophrenia [3,41]. There
has been a widespread belief that schizophrenia runs a
benign course in LAMIC countries. This belief stems
from the WHO multicenter studies which reported a
favorable outcome for patients living in developing
Figure 2 Kaplan-Meier Curve showing survival probability and treatment with antipsychotics in people with schizophrenia: a five-year
follow-up in Butajira, Ethiopia.
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time until reports started to emerge from LAMIC coun-
tries which challenged the idea that schizophrenia might
not run a benign course in these countries [13,14,25].
Short term outcome from our cohort showed that most
of our patients run a chronic non-remitting course [16].
A predominantly chronic non-remitting course coupled
with high mortality suggests a poor course and outcome
in this setting.
In this study we found that those who had insidious
onset had higher rate of mortality, whereas, those who
lived in rural areas had less mortality compared with
those living in urban areas. Treatment with antipsycho-
tic medication for at least 50% of the follow-up time
was associated with lower risk of mortality. In our ear-
lier report on course and outcome, treatment was the
most important predictor of good clinical course and
outcome. So, ensuring continued treatment with
Table 4 Association of mortality in schizophrenia with sociodemographic and clinical factors using Cox regression
model, Butajira Ethiopia
Characteristics Crude HR
(95%CI)
P-value Adjusted HR
(95% CI)
P-value
Sex
Male ref
Female 0.54 (0.19-1.52) 0.244
Age Group
15-24 ref ref
25-34 1.49 (0.55-4.09) 0. 43 1.85(0.46-7.43) 0.38
35-50 2.03 (0.75-5.51) 0.16 3.99(0.73-21.69) 0.11
Marital status
Single ref ref
Married 1.21 (0.57-2.56) 0.61 3.04(0.98-9.40) 0.053
Other 0.86 (0.31-2.37) 0.77 1.36(0.38-4.83) 0.633
Educational Status
No formal ref ref
Elementary 0.67 (0.31-1.44) 0.31 0.76(0.30-1.93) 0.56
Secondary 0.64 (0.24-1.68) 0.37 0.36(0.11-1.22) 0.10
Place of residence
Urban ref ref
Rural 0.49 (0.26-0.96) 0.038 0.34(0.14-0.80) 0.014*
Age of onset
≤ 19 ref ref
20-29 1.64 (0.69-3.88) 0.26 1.15(0.36-3.71) 0.81
≥ 30 1.78 (0.65-4.92) 0.26 1.07(0.24-4.67) 0.93
Duration of illness
≤ 2 yrs ref ref
> 2 yrs 1.38 (0.61-3.16) 0.44 0.73(0.25-2.13) 0.56
Speed of onset
Acute ref ref
Insidious 2.22 (1.04-4.72) 0.038 2.86(1.24-6.57) 0.013*
Schizophrenia subtype
Paranoid ref ref
Undifferentiated 1.09 (0.49-2.45) 0.82 0.66(0.25-1.75) 0.40
Other 1.52 (0.69-3.34) 0.30 0.90(0.33-2.43) 0.84
Antipsychotics 50%
≥ 50% ref ref
< 50% 2.12 (1.02-4.55) 0.044 2.66(1.054-6.72) 0.038*
* P < 0.05 significant difference
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outcome as well as reduce mortality in this cohort [16].
Strength and limitation of the study
To our knowledge this is the first community based
report on mortality in schizophrenia from the African
continent which adds to the knowledge base regarding
the mortality situation in schizophrenia worldwide.
The study was based on a mixed prevalence cohort
consisting of both acute and chronic cases and the
majority of the cohort had illness longer than two
years. Having a large number of chronic cases at enrol-
ment was considered a limitation as these patients
would die early in the course of the follow up period,
but ‘nature of onset’ rather than ‘duration of illness’
was associated with increased mortality in our cohort.
The other limitation was the information obtained on
the cause of death, which mostly relied on information
provided by family members. Post mortem examina-
tion data was not available. Furthermore it was not
possible to check the medical records of patients as
most of them died at home. Yet another limitation is
the lack of physical health checkup for patients in our
follow-up protocol which was only restricted to the
time of enrolment.
Conclusion
A six fold increase in mortality was noted compared
with the reference population in the area, an alarmingly
high level of mortality. Men were particularly vulnerable
to mortality as evidenced by the highest number of
death from both natural and unnatural causes. Further-
more most patients died from potentially treatable con-
ditions such as infections due to malaria and TB and
malnutrition. Unnatural causes such as suicide and acci-
dent were also important causes of death in this patient
population. Suicide was a very important cause of death
in the male patients. Another striking finding is that the
majority of patients died at home which suggests a pos-
sible neglect of these patients. The presence of malnutri-
tion as a cause death in these patients suggests a
possible discrimination and neglect at family level.
Again, the majority of patients were in severe psychotic
episode which showed the importance of the disorder
they had on causing their death. Patients need to have
regular medical evaluation and treatment besides psy-
chiatric care as most patients died from treatable medi-
cal conditions. They also need to have their basic needs
met such as availability food to prevent malnutrition.
Family and community education needs to be intensi-
fied. Ensuring continued treatment with antipsychotics
is also a feasible intervention to reduce mortality in this
setting.
Acknowledgements
We would like to acknowledge the Stanley Medical Research Institute (SMRI)
for funding the research project. SIDA/SAREC and Division of Psychiatry,
Department of Clinical Sciences, Umeå University, are gratefully
acknowledged for their support.
We would like to extend our gratitude to our diligent field workers and
research staff.
Families of our patients are gratefully acknowledged for their willingness to
participate in this study.
Author details
1Department of Psychiatry, School of Medicine, College of Health Sciences,
Addis Ababa University, Addis Ababa, Ethiopia.
2Aklilu Lemma Institute of
Pathobiology, College of Health Sciences, Addis Ababa University, Addis
Ababa, Ethiopia.
3Amanauel Specialized Mental Hospital, Addis Ababa,
Ethiopia.
4Division of Psychiatry, Department of Clinical Sciences, Umeå
University, Umeå, Sweden.
5Department of Psychological Medicine, Section
of Neurobiology of Mood Disorders, Institute of Psychiatry, King’s College
London, UK.
Authors’ contributions
ST, TS and AW carried out the data collection, participated in the analysis
and drafted the manuscript. TS, AF, AA, GK, and LS participated in the
design of the study and ST and GM performed the statistical analysis. TS, AF,
AA, GK and LS conceived of the study, and participated in its design and
coordination. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 25 August 2011 Accepted: 10 October 2011
Published: 10 October 2011
References
1. Allebeck P: Schizophrenia: A Life-Shortening Disease. Schizophr Bull 1989,
15:81-89.
2. Drew LR: Mortality and mental illness. Aust N Z J Psychiat 2005,
39:194-197.
3. Seeman MV: An Outcome Measure in Schizophrenia: Mortality. Can J
Psychiatry 2007, 52:55-60.
4. Brown S: Excess mortality of schizophrenia: A meta-analysis. Br J
Psychiatry 1997, 171:502-508.
5. Mortensen PB, Juel K: Mortality and causes of death in first admitted
schizophrenic patients. Br J Psychiatry 1993, 163:183-189.
6. Brown S, Barraclough B, Inskip H: Causes of the excess mortality of
schizophrenia. Br J Psychiatry 2000, 177:212-7.
7. Osby U, Correia N, Brandt L, Ekbom A, Spare’nP :Mortality and causes of
death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000,
45:21-28.
8. Joukamaa M, Heliövaara M, Knekt P, Aromaa A, Raitasalo R, et al: Mental
disorders and cause-specific mortality. Br J Psychiatry 2001, 179:498-502.
9. Heila H, Haukka J, Suvisaari J, Lönnquist J: Mortality among patients with
schizophrenia and reduced hospital care. Psychol Med 2005, 35:725-32.
10. Auquier P, Lancon C, Rouillon F, Lader M, Holmes C: Mortality in
schizophrenia. Pharmacoepidemiol Drug Saf 2006, 15:873-879.
11. Vinogradova Y, Coupland C, Hippisley-Cox J, Whyte S, Penny C: Effects of
severe mental illness on survival of people with diabetes. Br J Psychiatry
2010, 197:272-277.
12. Saha S, Chant D, McGrath J: A systematic review of mortality in
schizophrenia: is the differential mortality gap worsening over time?
Arch Gen Psychiatry 2007, 64:1123-1131.
13. Patel V, Cohen A, Thara R, Gureje O: Is the outcome of schizophrenia
really better in developing countries? Rev Bras de Psiquiatr 2006,
28:149-152.
14. Cohen A, Patel V, Thara R, Gureje O: Questioning an Axiom: Better
Prognosis for Schizophrenia in the Developing World? Schizophr Bull
2008, 34:229-244.
15. Mojtabai Varma VK, Malhotra V, Mattoo SK, Misra AK: Mortality and long-
term course in schizophrenia with a poor 2-year course: a study in a
developing country. Br J Psychiatry 2001, 178:71-75.
Teferra et al. BMC Psychiatry 2011, 11:165
http://www.biomedcentral.com/1471-244X/11/165
Page 8 of 916. Alem A, Kebede D, Fekadu A, Shibre T, Fekadu D: Clinical course and
outcome of schizophrenia in a predominantly treatment-naïve cohort in
rural Ethiopia. Schizophr Bull 2009, 35:646-654.
17. OPHCC: The 1994 Population and Housing Census of Ethiopia. Results for
Southern Nations, Nationalities and Peoples’ Region. Abridged Statistical Report
1996.
18. WHO: Composite International Diagnostic Interview, Core Version, 2.1 Geneva;
World Health Organization; 1997.
19. WHO: Schedules for Clinical Assessment in Neuropsychiatry, Version 2.1
Geneva; World Health Organization; 1997.
20. WHO: The ICD-10 Classification of Mental and Behavioural Disorders: Clinical
descriptions and diagnostic guidelines Geneva; World Health Organization;
1992.
21. Lulu K, Berhane Y: The use of simplified verbal autopsy in identifying
causes of adult death in a predominantly rural population in Ethiopia.
BMC Public Health 2005, 5:58.
22. Sartorius N, Gulbinat W, Harrison G, Laska E, Siegel C: Long-term follow-up
of schizophrenia in 16 countries. A description of the International
Study of Schizophrenia conducted by the World Health Organization.
Soc Psych Psych Epid 1996, 31:249-258.
23. Berhane Y, Byass P: Site description: physical geography of the Butajira DSA.
Butajira DSS; Ethiopia [http://paulaclark.name/CV/BOOK%20CHAPTERS/
population%20health%20and%20survival%20at%20indepth%20sites.html].
24. Harrison G, Hopper K, Craig T, Laska E, Siegel C, et al: Recovery from
psychotic illness: a 15- and 25-year international follow-up study. Br J
Psychiatry 2001, 178:506-517.
25. Ran MS, Chen EY, Conwell Y, Chan CL, Xiang YM, et al: Mortality in People
with Schizophrenia in Rural China: 10-Year Cohort Study. Br J Psychiatry
2007, 190:237-242.
26. Craig TJ, Ye Q, Bromet EJ: Mortality among first-admission patients with
psychosis. Compr Psychiatry 2006, 47:246-251.
27. Montout C, Casadebaig F, Lagnaoui R, Verdoux H, Philippe A, Begaud B,
et al: Neuroleptics and mortality in schizophrenia: prospective analysis of
deaths in a French cohort of schizophrenic patients. Schizophr Res 2002,
57:147-156.
28. Kurihara T, Kato M, Kashima H, Takebayashi T, Reverger R, et al: Excess
mortality of schizophrenia in the developing country of Bali. Schizophr
Res 2006, 83:103-105.
29. Chen WJ, Huang Y-J, Yeh L-L, Rin H, Hwu H-G: Excess mortality of
psychiatric inpatients in Taiwan. Psychiat Res 1996, 62:239-250.
30. Brown S, Kim M, Mitchell C, Inskip H: Twenty-five year mortality of a
community cohort with schizophrenia. Br J Psychiatrty 2010, 196:116-121.
31. Tesfaye S, Belyhun Y, Teklu T, Mengesha T, Petros B: Malaria prevalence
pattern observed in the highland fringe of Butajira, Southern Ethiopia: a
longitudinal study. Malar J 2011, 10:153.
32. Yassin M, Takele L, Gebresenbet S, Lera M, et al: HIV and Tuberculosis
Coinfection in the Southern Region of Ethiopia: A Prospective
Epidemiological Study. Scand J Infect Dis 2004, 36:670-673.
33. Fantahun M, Berhane Y, Ulf Högberg U, Stig Wall S, Peter Byass P: Young
adult and middle age mortality in Butajira demographic surveillance
site, Ethiopia: lifestyle, gender and household economy. BMC Public
Health 2008, 8:268.
34. Molla M, Byass P, Berhane Y, Lindtjorn B: Mortality Decreases among
Young Adults in Southern Central Ethiopia. Ethiop J Health Dev 2008,
22:218-225.
35. Abiodun OA: Mortality in a psychiatric population: a Nigerian psychiatric
hospital experience. Acta Psychiatr Scand 1988, 77:654-657.
36. Malomo IO, Aina OF, Ladapo HT, Owoeye AO: Ten-year mortality review in
a pioneer psychiatric hospital in West Africa. East Afr Med J 2003,
80:379-383.
37. Caldwell CB, Gottesman II: Schizophrenics Kill Themselves Too: A Review
of Risk Factors for Suicide. Schizophr Bull 1990, 16:571-589.
38. Harris EC, Barraclough B: Suicide as an outcome for mental disorders. A
meta-analysis. Br J Psychiatry 1997, 170:205-228.
39. Thara R, Honriotta M, Joseph A: Ten-year course of schizophrenia: the
Madras longitudinal study. Acta Psychiatr Scand 1994, 90:329-336.
40. Phillips MR, Yang G, Li S, Li Y: Suicide and the unique prevalence pattern
of schizophrenia in mainland China: a retrospective observational study.
Lancet 2004, 364:1062-68.
41. Bushe CJ, Taylor M, Haukka J: Review: Mortality in schizophrenia: a
measurable clinical endpoint. J Psychopharmacol 2010, 24:17-25.
42. Sartorius N, Jablensky A, Shapiro L: Two-year follow-up of the patients
included in the WHO International Pilot Study of Schizophrenia. Psychol
Med 1977, 7:529-541.
43. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, et al: Schizophrenia:
manifestations, incidence and course in different cultures: a World
Health Organization ten-country study. Psychol Med Monogr Suppl 1992,
20:1-97.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-244X/11/165/prepub
doi:10.1186/1471-244X-11-165
Cite this article as: Teferra et al.: Five-year mortality in a cohort of
people with schizophrenia in Ethiopia. BMC Psychiatry 2011 11:165.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Teferra et al. BMC Psychiatry 2011, 11:165
http://www.biomedcentral.com/1471-244X/11/165
Page 9 of 9